SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to <20ml/min/1.73m2 - PubMed
6 hours ago
- #chronic kidney disease
- #SGLT2 inhibitors
- #type 2 diabetes
- SGLT2 inhibitors are recommended for initiation when eGFR is ≥20ml/min/1.73m² in patients with type 2 diabetes and CKD.
- Continuation of SGLT2 inhibitors is advised even if eGFR falls below 20ml/min/1.73m², though data on efficacy and safety in this scenario are limited.
- A post-hoc analysis of the CREDENCE trial evaluated the effects of canagliflozin in patients whose eGFR deteriorated to <20ml/min/1.73m².
- Among 4,401 participants, 10.1% experienced eGFR deterioration to <20ml/min/1.73m², showing a higher risk of the primary composite outcome.
- Canagliflozin was associated with a lower risk of the primary outcome, regardless of eGFR deterioration, with no significant interaction effect.
- Adverse event rates were higher in patients with eGFR <20ml/min/1.73m² but similar between treatment groups.
- The study supports continuing SGLT2 inhibitors like canagliflozin in patients with eGFR <20ml/min/1.73m², showing persistent benefits for kidney and cardiovascular outcomes without additional safety concerns.